MiNK Therapeutics, Inc.
INKT
$11.71
-$0.48-3.90%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
12/6/2025
-
MarketBeat
12/5/2025
-
Insider Monkey
12/1/2025
-
MarketBeat
11/20/2025
-
GuruFocus
11/20/2025
-
GuruFocus
11/20/2025
-
GuruFocus
11/20/2025
-
The Fly
11/20/2025
-
Globe Newswire
11/17/2025
-
MarketBeat
11/15/2025
-
Insider Monkey
11/14/2025
-
GuruFocus
11/14/2025
-
GuruFocus
11/14/2025
-
Seeking Alpha: Transcripts
11/14/2025
-
SeekingAlpha
11/14/2025
-
Fool.com Headlines
11/14/2025
-
GuruFocus
11/14/2025
-
GuruFocus
11/14/2025
-
The Fly
11/14/2025
-
Globe Newswire
11/10/2025
-
MarketBeat
11/7/2025
-
TipRanks Financial Blog
11/7/2025
-
The Fly
11/7/2025
-
GuruFocus
11/7/2025
-
The Fly
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
--
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Friday, November 14, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 16 and 20 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
212 994 8250
Address
149 Fifth Avenue
New York, NY 10010
New York, NY 10010
Country
Year Founded
Business Description
Sector
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural...
more